Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD

Author(s):  
Cora M Best ◽  
Leila R Zelnick ◽  
Kenneth E Thummel ◽  
Simon Hsu ◽  
Christine Limonte ◽  
...  

Abstract Context The effect of daily vitamin D supplementation on the serum concentration of vitamin D (the parent compound) may offer insight into vitamin D disposition. Objective To assess the total serum vitamin D response to vitamin D3 supplementation and whether it varies according to participant characteristics. To compare results with corresponding results for total serum 25-hydroxyvitamin D (25(OH)D), which is used clinically and measured in supplementation trials. Design Exploratory study within a randomized trial. Intervention 2,000 International Units of vitamin D3 per day (or matching placebo). Setting Community-based. Participants 161 adults (mean ± SD age 70 ± 6 years; 66% males) with type 2 diabetes. Main Outcome Measures Changes in total serum vitamin D and total serum 25(OH)D concentrations from baseline to year 2. Results At baseline, there was a positive, nonlinear relation between total serum vitamin D and total serum 25(OH)D concentrations. Adjusted effects of supplementation were a 29.2 (95% CI: 24.3, 34.1) nmol/L increase in serum vitamin D and a 33.4 (95% CI: 27.7, 39.2) nmol/L increase in serum 25(OH)D. Among those with baseline 25(OH)D < 50 compared with ≥ 50 nmol/L, the serum vitamin D response to supplementation was attenuated (15.7 vs 31.2 nmol/L; interaction p-value = 0.02), whereas the serum 25(OH)D response was augmented (47.9 vs 30.7 nmol/L; interaction p-value = 0.05). Conclusions Vitamin D3 supplementation increases total serum vitamin D and 25(OH)D concentrations with variation according to baseline 25(OH)D, which suggests that 25-hydroxylation of vitamin D3 is more efficient when serum 25(OH)D concentration is low.

2020 ◽  
Author(s):  
Danial Alebouyeh ◽  
Nasrin Khalessi ◽  
Maryam Saboute ◽  
Maryam Alizadeh Chamkhaleh ◽  
Mandana Kashaki

Abstract Introduction. Vitamin D status is a key determinant of bone health and growth during childhood and adolescence. Therefore, we design a study to find out the association between the levels of serum vitamin D and need to consumption of vitamin D supplement.Method and materials. In this cross sectional study infants under 20 months referred to Ali Asghar Children's Hospital were included. Infants with maternal diseases and congenital malformations were excluded. All infants used vitamin D3 supplementation 400 IU per day from day fifth of birth. The level of 25-hydroxy vitamin D at the age of 1 years (month 12) were measured. Level of 25-hydroxy vitamin D in mothers were checked, too. Furthermore, we defined sufficient level of 25-hydroxy vitamin D ≥30ng/ml.Results. In this study, 68 infants under 20 months were examined. Half of them were boy. Mean age of infants was 16±3 months and mothers was 33±3 years old. In addition, the mean level of serum 25-hydroxy vitamin D in the infants were 40.99±13.86 ng/ml and in mothers were 31.39±13.14 ng/ml. 62.1% of mothers were in sufficient group and also 83% of infants had sufficient vitamin D level (25-hydroxy vitamin D ≥ 30ng/ml). There was not any significant correlation between vitamin D level in infants and mothers (P value=0.965). The mean level of serum vitamin D3 in boys was 39.55±3.79 ng/ml (12-51) and girls was 35.32±3.67 ng/ml (13.4-50). Similarly, significant relationship was not shown between gender and vitamin D of infants (P value = 0.437). Level of vitamin D in second children was significantly higher than first children (P value=0.011). The correlation between gestational age and vitamin D3 deficiency was also insignificant (P value=0.087). Head circumference (r= -0.404, P value=0.014) and age of mothers (r= 0.344, P value=0.04) correlated with vitamin D.Conclusion. In summary, we demonstrated most of the infants had sufficient vitamin D level at the age of 1 year. So it is recommended to continue vitamin D3 supplementation consumption.


2018 ◽  
Vol 74 (1) ◽  
pp. 91-98 ◽  
Author(s):  
Li Chen ◽  
Yanbin Dong ◽  
Jigar Bhagatwala ◽  
Anas Raed ◽  
Ying Huang ◽  
...  

Abstract Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (∆Age) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value = .046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value = .044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ∆Age only (p values = .002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.


2016 ◽  
Vol 64 (4) ◽  
pp. 929.2-930
Author(s):  
V Jetty ◽  
G Duhon ◽  
P Shah ◽  
M Prince ◽  
K Lee ◽  
...  

BackgroundIn ∼85–90% of statin intolerant patients, vitamin D deficiency (serum 25 (OH) D <32 ng/ml) is a reversible cause of statin intolerance, usually requiring 50,000 to 100,000 units of vitamin D/week continuously to normalize serum vitamin D, and thus successfully allow reinstitution of statins which previously could not be tolerated because of myalgia-myositis.Specific AimIn 274 statin intolerant patients, all with low entry serum vitamin D (<32 ng/ml, median 21 ng/ml), we assessed safety and efficacy of vitamin D supplementation (50,000–100,000 units/week) over treatment periods of 3 months (n=274), 3 and 6 months (n=161), 3, 6, and 9 months (n=58), and 3, 6, 9, and 12 months (n=22).ResultsIn the 385 patients with 3 month follow-up, taking mean 61,000 and median 50,000 IU of vitamin D3/week, median serum vitamin D rose from 20 to 42 ng/ml (p<0.0001); vitamin D became high (>100 ng/ml) but not toxic-high (>150 ng/ml) in 4 patients (1.0%) (101, 102, 106, 138 ng/ml). Median serum calcium was unchanged from entry (9.6 mg/dl) to 9.6 at 3 months. On vitamin D supplementation, the trend of change in serum calcium from normal-to-high or from high-to-normal did not significantly differ (McNemar S=1.0, p=0.32), and there was no significant trend in change of the calculated glomerular filtration rate (eGFR) from entry to follow-up (McNemar S=2.6, p=0.11).In the 161 patients with 3 and 6 month follow-up, taking mean 67,000 and median 50,000 IU of vitamin D3/week, median entry serum vitamin D rose from 21 to 42 to 44 ng/ml (p<0.0001), serum vitamin D was high (>100 but <150 ng/ml) in 2 patients at 3 months (1.2%, 101, 102 mg/ml) and in 3 (1.9%) at 6 months (101, 140, 140 ng/ml). Median serum calcium was unchanged from entry (9.7 mg/dl), at 3 and 6 months (9.7, 9.6 mg/dl, p>0.05). On vitamin D supplementation, the change in serum calcium from normal-to-high or high-to-normal was no significant trend (McNemar S=0.7, p=0.41), and no trend in change of eGFR (McNemar S=1.3, p=0.26).In the 58 patients with 3, 6, and 9 month follow-up on mean and median 71,000 and 100,000 IU of D3/week, median entry vitamin D rose from 20 to 37, 41, and 44 ng/ml (p<0.0001), with 1 (1.7%, 102 ng/ml), 2 (3.5%, 140, 140 ng/ml), and 0 (0%) patients high. Median serum calcium was unchanged from entry, median 9.7, 9.8, 9.6, and 9.6 mg/dl. On vitamin D supplementation, the trend of change in serum calcium from normal-to-high or high-to-normal was not significant (McNemar S=1.8, p=0.18), and no trend in change of eGFR (McNemar S=2, p=0.16).In the 22 patients with follow-up at 3, 6, 9, and 12 months on mean and median 70,000 and 75,000 IU of D3/week, median serum vitamin D rose from 20 to 37, to 41, to 44, and to 43 ng/ml (p<0.0001), with 1 (5%, 102 ng/ml) high, 2 (9%, 140, 140) high, 0 (0%) high, and 1 (5%, 126 ng/ml) high. Serum calcium was unchanged, median at entry 9.6, and then at 3, 6, 9, and 12 months 9.7, 9.7, 9.5, and 9.7 mg/ml. At entry serum calcium was normal in 21, none high, and one became high at 12 month follow-up. The trend of change in eGFR was insignificant, McNemar S=1.0, p=0.32.When serum D rose above 100 ng/ml in the few cases, as above, it fell into the normal range within 2 weeks by reducing the vitamin D dose by 50%.ConclusionsWhen 50,000–100,000 units of vitamin D/week are given to reverse statin intolerance in statin intolerant patients with low entry vitamin D (<32 ng/ml), it appears to be safe over up to 1 year follow-up, without toxic high serum vitamin D levels >150 ng/ml, and levels rarely >100 ng/ml, and without changes in serum calcium or eGFR.


2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 760-760
Author(s):  
Jennifer Schrack ◽  
Jacek Urbanek ◽  
Amal Wanigatunga ◽  
Stephen Juraschek ◽  
Christine Mitchell ◽  
...  

Abstract Cross-sectional evidence suggests older adults with higher serum vitamin D are more physically active, but whether long-term vitamin D supplementation attenuates age-related declines in physical activity (PA) is undefined. We examined the association between vitamin D supplementation and daily PA in 639 STURDY participants (aged 77 (5.4) years; 44% women) over up to 24-months. Participants were randomized to receive 200 (n=275), 1000 (n=168), 2000 (n=59), or 4000 (n=63) IU/day of vitamin D3. PA was measured using the Actigraph Link wrist-worn accelerometer 24 hours/day for 7-days at baseline, 3, 12, and 24 months. In linear mixed models adjusted for baseline PA level, total daily PA appeared to decline (β=-43.3 counts, p=0.06) annually for all groups and there was no difference by vitamin D3 dose (p for group*time =0.14). These results suggest daily vitamin D supplementation has no effect on quantities of daily PA.


2019 ◽  
Author(s):  
Reiva Farah Dwiyana ◽  
Pramita K.C. Nugrahaini ◽  
D.P. Larasati ◽  
Inne Arline Diana ◽  
Reti Hindritiani ◽  
...  

Vitamin D deficiency is a condition often found in various autoimmune diseases, including vitiligo. There were clinical improvements in autoimmune patients who had been given oral vitamin D supplementation, as well as vitiligo patients. This study aimed to analyze the comparison effect of a combination therapy of 308-nmexcimer light phototherapy and vitamin D3 supplementation toward 308-nm-excimer light phototherapy alone to increase of serum 25-(OH)D levels in childhood vitiligo patients. Subjects consisted of 16 childhood vitiligo patients that divided into two groups; group I was given a combination of 308-nm-excimer light phototherapy and 5000 IU of vitamin D3 supplement once daily, while group II was given monotherapy of excimer light. There were highly significant increase of 25-(OH)D serum in both groups which were 324.00±119.066% and 29.84±36.106%, respectively. The very significant result was seen in a comparison of average increased of serum 25-(OH)D levels between both groups. The study concluded that combination of 308-nm-excimer light phototherapy and vitamin D3 supplementation gave a better effect than phototherapy only to increase of serum 25- (OH)D levels in childhood vitiligo patients.


2016 ◽  
Vol 102 (1) ◽  
pp. 100-110 ◽  
Author(s):  
Pang Yao ◽  
Liang Sun ◽  
Ling Lu ◽  
Hong Ding ◽  
Xiafei Chen ◽  
...  

Abstract Context: Little is known about how genetic and nongenetic factors modify responses of vitamin D supplementation in nonwhite populations. Objective: To investigate factors modifying 25-hydroxyvitamin D [25(OH)D] and bioavailable 25(OH)D [25(OH)DBio] responses after vitamin D3 supplementation. Design, Setting, Participants, and Intervention: In this 20-week, randomized, double-blinded, placebo-controlled trial, 448 Chinese with vitamin D deficiency received 2000 IU/d vitamin D3 or placebo. Main Outcome Measures: Serum 25(OH)D, vitamin D-binding protein (VDBP), parathyroid hormone (PTH) and calcium were measured, and 25(OH)DBio was calculated based on VDBP levels. Six common polymorphisms in vitamin D metabolism genes were genotyped. Results: Between-arm net changes were +30.6 ± 1.7 nmol/L for 25(OH)D, +2.7 ± 0.2 nmol/L for 25(OH)DBio, and −5.2 ± 1.2 pg/mL for PTH, corresponding to 70% [95% confidence interval (CI), 62.8% to 77.2%] net reversion rate for vitamin D deficiency at week 20 (P &lt; 0.001). Only 25(OH)DBio change was positively associated with calcium change (P &lt; 0.001). Genetic factors (GC-rs4588/GC-rs7041, VDR-rs2228570, and CYP2R1-rs10741657; P ≤ 0.04) showed stronger influences on 25(OH)D or 25(OH)DBio responses than nongenetic factors, including baseline value, body mass index, and sex. An inverse association of PTH-25(OH)D was demonstrated only at 25(OH)D of &lt;50.8 (95% CI, 43.6 to 59.0) nmol/L. Conclusions: Supplemented 2000 IU/d vitamin D3 raised 25(OH)D and 25(OH)DBio but was unable to correct deficiency in 25% of Chinese participants, which might be partially attributed to the effect of genetic modification. More studies are needed to elucidate appropriate vitamin D recommendations for Asians and the potential clinical implications of 25(OH)DBio.


2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Mohammad J. Alkhatatbeh ◽  
Haneen S. Almomani ◽  
Khalid K. Abdul-Razzak ◽  
Shaher Samrah

AbstractThere are complex potential inter-relationships between the chronic inflammation of asthma and poor control, vitamin D deficiency, musculoskeletal pain and anxiety and depression. The aim was to investigate associations between vitamin D and these possible co-morbidities. This case-controlled study involved 75 adults with asthma and 75 controls. Serum 25-hydroxyvitamin D (25(OH)D) was measured, levels of anxiety, depression, musculoskeletal pain, and asthma control were assessed. Participants with asthma had lower 25(OH)D and higher anxiety scores and higher measures of musculoskeletal pain compared to controls. Binary logistic regression showed that asthma was associated with decreased 25(OH)D (Odds ratio (OR) = 0.86), general weakness (OR = 13.29), complaint of musculoskeletal pain (OR = 13.73), and increased intensity of musculoskeletal pain (OR = 0.61) and number of painful sites (OR = 2.58). Asthma was not associated with anxiety or depression. Further studies are required to investigate if vitamin D supplementation can improve asthma symptoms and musculoskeletal pain.


Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 4047
Author(s):  
Mustafa Sait Gönen ◽  
Merve Alaylıoğlu ◽  
Emre Durcan ◽  
Yusuf Özdemir ◽  
Serdar Şahin ◽  
...  

Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.


2020 ◽  
Author(s):  
JianWen Duan ◽  
YongSheng Chen ◽  
WenFei Wu ◽  
Cong Xiong ◽  
ZuLiang Hu ◽  
...  

Abstract Background: The relation and possible mechnism of vitamin D supplementation on depression in colorectal cancer (CRC) patients was not clearly ; Objective: This study investigates the effect of vitamin D supplementation on depression in colorectal cancer (CRC) patients. Methods : We recruited 168 CRC patients and 168 healthy control subjects into this study. 17-item Hamilton Depression Rating Scale (HDRS-17) was used to assess depression. Results: We found that 25-hydroxyvitamin D (25(OH)D) concentrations were independently associated with depression among CRC patients. For the 45 depressed patients receiving vitamin D3 supplementation, depression scores decreased markedly with 25(OH)D concentrations increasing to normal. Conclusion: Therefore, we advise monitoring this indicator in CRC patients and supplementing with vitamin D 3 when their 25(OH)D concentrations are low.


2021 ◽  
Vol 4 (2) ◽  
pp. 112-117
Author(s):  
Raphael Kosasih ◽  
Diana Sunardi

Abstract Introduction: Vitamin D deficiency has become more prevalent around the world along with a sedentary lifestyle and limited exposure to sunlight. Deficiencies of vitamin D in lactating mothers could cause deficiencies in their infants and vitamin D deficient infants are at higher risk of having infectious diseases. Supplementation of Vitamin D to lactating mothers may benefit both mothers and infants to reduce infection morbidity. Methods: Relevant literature research was conducted in PubMed, Cochrane, and SciELO using relevant keywords and advanced search methods. Relevant literature was then screened for duplication, relevance, and eligibility. Results: A randomized-controlled trial was selected. The study showed that supplementation of 3000µg oral vitamin D3 to lactating mothers significantly raise their infants' serum vitamin D (p<0.01) and reduce infection morbidity (p<0.01) Conclusions: Oral supplementation of vitamin D3 could be given to lactating mothers to improve their infants' serum vitamin D and reduce infection morbidity. Keywords: vitamin D, lactation, infants' infection


Sign in / Sign up

Export Citation Format

Share Document